Skip to main content
. Author manuscript; available in PMC: 2022 Feb 20.
Published in final edited form as: Nat Immunol. 2021 Aug 20;22(10):1306–1315. doi: 10.1038/s41590-021-01021-0

Fig. 4. Efficacy of mRNA-1273 against upper and lower respiratory B.1.351 viral replication.

Fig. 4.

Twenty-four rhesus macaques were immunized and challenged as described in Extended Data Fig. 1, and compared to eight age-matched controls. BAL (A, C) and nasal swabs (NS) (B, D) were collected on days 2 (circles), 4 (squares), and 7 (triangles), and 14 (inverted triangles) post-challenge, where applicable, and viral replication was assessed by detection of SARS-CoV-2 E- (A-B) and N-specific (C-D) sgRNA. Viral titers were assessed by TCID50 assay for BAL collected on days 2 and 4 post-challenge (E) and for NS on day 2 (H). Boxes and horizontal bars denote the IQR and medians, respectively; whisker end points are equal to the maximum and minimum values. (F-G, I-J) Plots show correlations between viral titers and sgRNA_E (F, I) and sgRNA_N (G, J) in BAL (F-G) and NS (I-J) 2 days post-challenge. Data represents one independent experiment. Black and gray lines indicate linear regression and 95% confidence interval, respectively. ‘r’ and ‘p’ represent Spearman’s correlation coefficients and corresponding two-sided p-values, respectively; all p-values were <0.0001. Symbols represent individual NHP and may overlap for equal values.